摘要
目的观察艾塞那肽对2型糖尿病患者C肽的影响及临床疗效。方法选取2012年1月至2013年6月在新桥医院内分泌科住院的2型糖尿病患者78例,分为治疗组(n=39),给予二甲双胍联合艾塞那肽治疗,包括男性16例,女性23例,年龄(49.0±6.0)岁;对照组(n=39),给予二甲双胍联合甘精胰岛素治疗,包括男性21例,女性18例,年龄(50.1±5.9)岁。两组均治疗16周。监测并分析两组治疗前后空腹及餐后2 h C肽、空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-hour postprandial blood glucose,2hPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、体质量指数(BMI)等相关指标的变化。结果治疗16周后治疗组空腹及餐后2 h C肽水平[(2.34±0.51)、(2.66±0.99)ng/mL]均较治疗前[(1.89±0.63)、(1.09±0.46)ng/mL]有所增高(P<0.05),但对照组C肽治疗前后无明显变化(P>0.05);两组患者治疗后的FBG、2hPG、HbA1c[治疗组治疗后分别为(6.94±0.75)、(9.98±0.85)mmol/L,(6.87±0.89)%]均较治疗前[治疗组治疗前分别为(10.06±1.98)、(12.3±0.75)mmol/L,(8.89±1.15)%]有所降低(P<0.05),且两组之间差异无统计学意义(P>0.05);两组患者体质量、腹围及BMI均较治疗前有所下降,治疗组降低更明显(P<0.05)。结论艾塞那肽联合二甲双胍在提高2型糖尿病患者的C肽水平的同时能够降低患者的血糖、HbA1c、体质量、腹围及BMI。
Objective To determine the effects of exenatide on the expression of C-peptide and on the clinical outcome in the treatment of type 2 diabetes. Methods A total of 78 hospitalized patients with type 2 diabetes in our department from January 2012 to June 2013 were prospectively recruited, and then divided into 2 groups, the control group and the treatment group. The treatment group had 39 patients, including 16 males and 23 females, at an average age of 49.0± 6.0, and received metformin combined with exenatide. Whereas, there were 39 patients in the control group, including 21 males and 18 females, with the average age of 50.1 ± 5.9 and being given metformin combined with Gansulin. All these patients were treated for 16 weeks. The indicates, including fasting glycosylated hemoglobin （ HbA1 c） between 2 groups before and after postprandial C-peptide levels were blood glucose （ FBG ）, 2-hour postprandial blood glucose （ 2hPG ）, , fasting C-peptide, 2-hour postprandial C-peptide, and BMI were compared treatment. Results At 16 weeks after the treatment, the fasting and 2-h increased in the treatment group （P 〈 0.05 ）, but the control group had no obvious change in the 2 indicators （P 〉 0.05 ）. FBG, 2hPG and HbAlc were significantly decreased in the both 2 groups （ P 〈 0.05 ）, but there was no statistical difference between them （ P 〉 0.05 ）. The body weight, circumference of abdomen, and BMI of all the patients were decreased, and the decrease was more significantly in the treatment group than in the control group （ P 〈 0. 05 ）. Conclusion Exenatide combined with metformin effectively improves the C-peptide level, and reduces blood glucose, HbAlc, body weight, circumference of abdomen and BMI in the patients with type 2 diabetes.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2014年第15期1604-1606,共3页
Journal of Third Military Medical University
